Form 4: iRhythm CBO/CLO Murphy Granted 7,024 RSUs

iRhythm Holdings, Inc. reports a future grant of 7,024 Restricted Stock Units to Patrick Michael Murphy, Chief Business Officer and Chief Legal Officer, vesting over four years.

Summary

• Patrick Michael Murphy, Chief Business Officer and Chief Legal Officer of iRhythm Holdings, Inc. (IRTC), was granted 7,024 Restricted Stock Units (RSUs).
• Each RSU represents a contingent right to receive one share of the company's Common Stock.
• The transaction date for this acquisition is February 25, 2026, and it was made pursuant to a Rule 10b5-1 plan.
• The RSUs will vest over a four-year period, with 25% vesting on March 1, 2027, and an additional 25% on each subsequent one-year anniversary, contingent on Mr. Murphy's continued service.
• Following this reported transaction, Mr. Murphy will beneficially own 67,560 shares of Common Stock.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a moderately positive development, reflecting standard executive compensation practices aimed at retention and alignment, with minimal direct impact on immediate share price.

Positives

• Aligns executive interests with shareholder value through equity ownership, incentivizing long-term performance.
• Serves as a retention incentive for a key executive (Chief Business Officer and Chief Legal Officer) through a multi-year vesting schedule.

Negatives

• Potential for minor future dilution upon the vesting and conversion of RSUs into common stock.

Risks

• The vesting of the Restricted Stock Units is contingent on the reporting person's continued service, meaning the shares are not guaranteed if employment ceases before vesting dates.

Future Outlook

NA

Industry Context

StockSavvy.ai notes that granting Restricted Stock Units (RSUs) to key executives like the Chief Business Officer and Chief Legal Officer is a standard practice in the medical device and healthcare technology industry. This form of equity compensation is widely used to attract, retain, and incentivize top talent by aligning their long-term financial interests with the company's performance and shareholder value creation.

Comparison to Industry Standards

• The grant of RSUs with a multi-year vesting schedule is a common executive compensation structure, similar to practices at peer companies in the medical technology sector such as Medtronic (MDT), Abbott Laboratories (ABT), and Boston Scientific (BSX), which frequently use RSUs to incentivize long-term performance and retention.
• The specific number of RSUs (7,024) would need to be evaluated against Mr. Murphy's overall compensation package and the company's size and performance metrics to determine if it aligns with industry benchmarks for executives in similar roles and company stages.

Stakeholder Impact

• Shareholders: Minor potential future dilution upon RSU vesting, but also increased alignment of executive interests with shareholder value.
• Employees: Signals continued investment in executive talent and standard compensation practices.

Next Steps

• Continued service by Patrick Michael Murphy to ensure vesting of RSUs.
• Future vesting events on March 1, 2027, and subsequent anniversaries.

Key Dates

Recommendation

This Form 4 filing details a routine executive equity grant, which is a standard component of compensation and retention strategies. It does not present new information that would significantly alter the fundamental investment thesis for iRhythm Holdings, Inc., warranting a 'hold' recommendation based solely on this filing.

Keywords

iRhythm Holdings, IRTC, Form 4, Insider Transaction, Restricted Stock Units, RSU, Executive Compensation, Patrick Michael Murphy, CBO, CLO, Equity Grant, Vesting, 10b5-1 Plan